

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Daryl T. Baldwin et al.

Serial No.: 10/658482

Filed: 09/09/2003

For: Novel Composition and Methods for

the Treatment of Immune Related

Diseases

Group Art Unit: 1645

Examiner: Not yet assigned

Confirmation No: 3368

Customer No: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

February 6, 2004

Jennifer Fisk

### REQUEST FOR A CORRECTED FILING RECEIPT

Mail Stop: Office of Initial Patent Examination

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as indicated in red on the attached copy and as follows:

In the "Applicant(s)" section, please amend to read as follows: instead of "Andrew C. Chen", please insert --Andrew C. Chan--

At least one of the above corrections is due to applicant's error and the fee therefor under 37 CFR 1.19(h) is applicable. Please charge Deposit Account 07-0630 in the amount of \$25.00 to cover the cost.

Respectfully submitted,

GENENTECH, INC

Date: February 6, 2004

David A. Carpenter

Reg. No. 45,945

Telephone No. (650) 225-3733

packe la



## United States Parket and Fademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. DOI: 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

 APPL NO.
 FILING OR 371 (c) DATE
 ART UNIT
 FIL FEE REC'D
 ATTY DOCKET NO
 DRAWINGS
 TOT CLMS
 IND CLMS

 10/658,482
 09/09/2003
 1645
 2022
 P1974R1
 4
 30
 13

**CONFIRMATION NO. 3368** 

FILING RECEIPT

\*OC000000011382453\*

Date Mailed: 12/01/2003

09157 GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISCO, CA 94080

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Daryl T. Baldwin, Berkeley, CA; Sarah C. Bodary, Palo Alto, CA; Andrew C. Chen, Menlo Park, CA; Hilary Clark, San Francisco, CA; Janet K. Jackman, Half Moon Bay, CA; William I. Wood, Hillsborough, CA;

#### **Assignment For Published Patent Application**

Genentech, Inc., South San Francisco, CA;

#### Domestic Priority data as claimed by applicant

This appln claims benefit of 60/410,062 09/11/2002

Foreign Applications

If Required, Foreign Filing License Granted: 11/29/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Novel composition and methods for the treatment of immune related diseases

**Preliminary Class** 

435

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).